BioSpace News Archive

Today, Arthur Kapoor, president and CEO of HealthEC, and Jay Rosen, founder and president of Health Management Associates (HMA), announced the two firms have engaged in an effort designed to accelerate improvements in healthcare service delivery and outcomes.

Calmare Therapeutics Incorporated announced that the independent medical review organization, in a rereview case filed with the California Department of Insurance, recommended overturning an insurance treatment coverage denial by the UnitedHealthcare Insurance Company for Calmare Pain Mitigation Therapy™ in the treatment of Complex Regional Pain Syndrome.

ArisGlobal, the leading provider of life sciences software that automates drug development functions for over 300 life sciences companies, today announced that a large, top five global biopharmaceutical company has selected its LifeSphere MultiVigilance safety system as the foundation of its next-generation pharmacovigilance technology environment. I

To make it easier for members to fill and manage multiple prescriptions, Horizon Healthcare Services, Inc. (Horizon), New Jersey’s oldest and largest health insurer, and its pharmacy benefit manager Prime Therapeutics LLC, now offer its members an integrated pharmacy experience with PillPack by Amazon Pharmacy.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their collaboration with Verseau Therapeutics for the development and delivery of a systems pharmacology model that will be used for efficacious dose prediction for the treatment of cancer.

Cytovia Therapeutics, Inc, an emerging biopharmaceutical company developing natural killer immunotherapies for cancer, announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy.

Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, announced the appointment of Peter G. Traber, MD, to the position of Chief Medical Officer.

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced plans to report second quarter 2020 financial results on Monday, August 10, 2020, before market open.

Salarius Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $1.20 per share.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced the appointment of Heidy Abreu King-Jones to the newly created role of Chief Legal Officer.